Avidor Shulman

This inventor holds 18 USPTO granted patents and 18 published patent applications and 11 EPO patents, primarily in Biotechnology Innovations. Top assignees: Protalix Ltd., Biond Biologics Ltd., Biond Biologies Ltd.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Avidor Shulman. Retrieved from https://idiyas.com/inventor/avidor-shulman-dqgjlsd0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 18)

% Patents Active = 88.9

EPO Patents = 11 (Patent Applications = 22)

Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 17(Granted Patents)

Location History:

Rakefet-Doar-Na Misgav, IL (2014)
Rakefet, IL (2015 - 2024)

Company Filing History:

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Stabilized Alpha-Galactosidase

Anti-ILT2 Antibodies

Intracellular Delivery

Nucleic Acid Construct

Inhalable Formulations

Dry Powder Formulations

Saccharide-Conjugates

Modified DNase

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12589163 - SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY (2026-03-31),

2. 12544451 - INTRACELLULAR DELIVERY COMPOSITIONS (2026-02-10),

3. 12503510 - SMALL SHEDDING BLOCKING AGENTS (2025-12-23),

4. 12391755 - Methods of use for anti-ILT2 antibodies (2025-08-19),

5. 12385026 - Stabilized alpha-galactosidase and uses thereof (2025-08-12),

6. 12139534 - Methods and compositions for decreasing soluble immune receptor CD28 (2024-11-12),

7. 12071479 - Antibodies against ILT2 and use thereof (2024-08-27),

8. 11814657 - Modified DNase and uses thereof (2023-11-14),

9. 11236162 - Antibodies against ILT2 (2022-02-01),

10. 11225648 - Modified DNase and uses thereof (2022-01-18),

11. 10870842 - Stabilized alpha-galactosidase and uses thereof (2020-12-22),

12. 10280414 - Stabilized α-galactosidase and uses thereof (2019-05-07),

13. 9732333 - Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells (2017-08-15),

14. 9708595 - Stabilized alpha-galactosidase and uses thereof (2017-07-18),

15. 9603907 - Dry powder formulations of dNase I (2017-03-28),

Title: Avidor Shulman: Innovator in Biopharmaceuticals

Introduction

Avidor Shulman is a prominent inventor based in Rakefet, Israel. He has made significant contributions to the field of biopharmaceuticals, holding a total of 18 patents. His work focuses on innovative treatments and methodologies that have the potential to impact cancer therapy and genetic disorders.

Latest Patents

Among his latest patents, Shulman has developed methods of use for anti-ILT2 antibodies. This invention provides monoclonal antibodies against ILT2, along with pharmaceutical compositions and methods for producing them. The invention also includes methods for treating cancer by administering these antibodies or compositions. Another notable patent is for stabilized alpha-galactosidase and its uses. This patent describes multimeric protein structures comprising alpha-galactosidase monomers linked via a moiety, which are designed to treat Fabry disease. These structures demonstrate improved performance in terms of enhanced activity and longevity under various conditions.

Career Highlights

Shulman has worked with several notable companies in the biopharmaceutical sector, including Protalix Ltd. and Biond Biologics Ltd. His experience in these organizations has contributed to his expertise in developing innovative treatments and therapies.

Collaborations

Throughout his career, Avidor Shulman has collaborated with talented individuals such as Yoseph Shaaltiel and Ilya Ruderfer. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of biopharmaceutical research.

Conclusion

Avidor Shulman is a distinguished inventor whose work in biopharmaceuticals has led to significant advancements in cancer treatment and genetic disorders. His innovative patents and collaborations highlight his commitment to improving healthcare through scientific research and development.

Profile summary based on public USPTO records.